Coagulation and fibrinolysis in patients with resistance to thyroid hormone due to a thyroid hormone receptor β-gene mutatio

Completed

• Conditions: insensitivity for thyroid hormone because of a change in the DNA; 10043739; thyroid hormone resistance because of a gene mutation; 10083624; 10014523

• Registration Number: NL-OMON38471
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 36

Inclusion Criteria

- Patients with thyroid hormone resistance due to a mutation in the thyroid hormone receptor beta gene
- Elevated T3 and/or T4 according to the local reference ranges;For the control groups:
a) hyperthyroid patients with elevated serum T4 and/or T3 according to the local reference ranges
b) euthyroid controls with general good health, both matched for age (± 5 years) and gender

Exclusion Criteria

- No informed consent
- Oral anticoagulant therapy (warfarin, vitamin K antagonists)
- Hemophilia or von Willebrand's disease
- Oral corticosteroid therapy
- Previous VTE within the last 6 months
- Previous thyroid surgery or radio-iodine treatment
- Current anti-thyroid drugs

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The following groups of lab markers will be tested: labmarkers: thyroid<br /><br>function and SHBG, coagulation markers and fibrinolysis markers.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable</p><br>